Stoke Therapeutics (NASDAQ:STOK) Shares Up 4.5%

Stoke Therapeutics, Inc. (NASDAQ:STOK) shot up 4.5% during trading on Thursday . The stock traded as high as $12.26 and last traded at $12.25. 228,273 shares traded hands during trading, a decline of 76% from the average session volume of 960,156 shares. The stock had previously closed at $11.72.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on STOK. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 26th. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. Canaccord Genuity Group boosted their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. boosted their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday, March 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, April 11th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.63.

Stoke Therapeutics Stock Up 3.4 %

The company has a market cap of $557.92 million, a PE ratio of -5.08 and a beta of 0.77. The company has a 50-day moving average of $8.76 and a 200-day moving average of $5.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to analysts’ expectations of $3.70 million. As a group, equities analysts predict that Stoke Therapeutics, Inc. will post -2.28 EPS for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at approximately $423,035. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,632,741 shares of company stock valued at $41,983,115. Insiders own 12.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Stoke Therapeutics by 24.3% in the second quarter. BlackRock Inc. now owns 2,293,670 shares of the company’s stock valued at $24,382,000 after buying an additional 448,175 shares during the period. Vanguard Group Inc. raised its stake in shares of Stoke Therapeutics by 2.7% in the third quarter. Vanguard Group Inc. now owns 2,047,904 shares of the company’s stock valued at $26,295,000 after buying an additional 52,871 shares during the period. Lynx1 Capital Management LP bought a new stake in shares of Stoke Therapeutics in the third quarter valued at $6,738,000. Goldman Sachs Group Inc. raised its stake in shares of Stoke Therapeutics by 976.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,391,431 shares of the company’s stock valued at $7,319,000 after buying an additional 1,262,126 shares during the period. Finally, Wellington Management Group LLP bought a new stake in shares of Stoke Therapeutics in the first quarter valued at $25,011,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.